International Clinical Study of Zhizhu Kuanzhong Capsule

Functional Dyspepsia Clinical Trial

Official title:

A Multi-center, Randomized, Double-Blind, Placebo-Controlled Parallel Group Clinical Trial of Zhizhu Kuanzhong Capsule in Treating Patients With Postprandial Distress Syndrome of Functional Dyspepsia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03825692
• Other study ID #: 2017YFC1703703
• Status: Recruiting
• Phase: Phase 4
• Start date: October 24, 2019
• Est. completion date: December 2023

Study information

• Verified date: January 2023
• Source: Xiyuan Hospital of China Academy of Chinese Medical Sciences
• Contact: Fang Lu, MD,Phd
• Phone: +861062835652
• Email: deerfang[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This trial aims to evaluate the clinical efficacy and safety of Zhizhu Kuanzhong Capsule in the treating patients with functional dyspepsia postprandial distress syndrome(FD PDS). Half of participants will receive Zhizhu Kuanzhong Capsule,while the other will receive a placebo.

Description:

Functional dyspepsia (FD) is one of the most common functional gastrointestinal disorders. Current data from clinical studies have shown that traditional Chinese medicine can obviously relieve clinical symptoms of patients with FD, and has special advantages and good clinical application prospects in the treatment of FD. Zhizhu Kuanzhong Capsule is mainly composed of the following 4 kinds of Chinese herbs: Rhizoma Atractylodis Macrocephala, Fructus Aurantii Immaturus, Radix Bupleuri and Fructus Crataegi. This trial aims to evaluate the clinical efficacy and safety of Zhizhu Kuanzhong Capsule in the treating patients with functional dyspepsia postprandial distress syndrome(FD PDS). This is a multi-center, stratified-block randomized, double-blind and placebo parallel-controlled trial. The comparison between the investigational drug and the placebo will be conducted with superiority design. About 480 subjects matched Rome IV diagnostic criteria for FD PDS will be enrolled. For each subject, this study includes a 0-2 week screening period, a 1-week run-in period, an 8-week double-blind treatment period, and a 4-week follow-up period. The drugs used in the clinical study (including investigational drug and placebo) will be supplied by Shuangren Pharmaceutical Co., Ltd. of Lonch Group.The quality standards and test methods for the placebo are consistent with those for the investigational drug, and the quality test meets the proposed quality standards. The selection and evaluation bias are controlled by means of strictly implementing randomized control blinded method etc, and the investigator will be trained on the consistency of scale evaluation.The electronic case report form (hereinafter referred to as eCRF) of this trial is created using the Medical Clinical Trial Data Management System (eCDMS3.0) for online data acquisition and management via the Internet. The data in the eCRF are from the original documents such as the original medical records and the physicochemical examination report sheets and should be consistent with the original documents. The response rate for functional dyspepsia VAS score will be compared between the test group and control group at 8 weeks after randomization.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 480
• Est. completion date: December 2023
• Est. primary completion date: December 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Meeting the Rome IV diagnostic criteria for functional dyspepsia-postprandial distress syndrome;

2. * At least 3 days during the one-week run-in period with VAS score = 4 for major symptoms (at least one of postprandial fullness discomfort and early satiety) .

3. Age between 18 and 65 years old (including 18 and 65 years old), male or female, outpatients;

4. **Be able to discontinue prohibited medications that may affect the evaluation of the effectiveness, such as acid inhibition/antacids, prokinetic agents, non-steroidal anti-inflammatory drugs, anticholinergic agents, glucocorticoids, and therapeutic medication for H. pylori eradication.

5. Each subject is informed and voluntarily signed the informed consent form(ICF).

• Subjects who entered the one-week run-in period are self-rated on the Visual Analogue Score (VAS) for the degree of discomfort with both symptoms of postprandial fullness and early fullness, with subjects indicating the degree of discomfort on a 10 cm ruler marked 0- "Asymptomatic or No Discomfort"and 10- "Extreme Severe or Extreme Discomfort"at its head and tail, respectively. The rating was made once a day and 7 days a week with scores of 0 to 10.

• A 2-week wash-out period is required for patients taking prohibited medications prior to screening.

Exclusion Criteria:

1. Gastroscopic findings of gastric cancer, peptic ulcer, erosive gastritis (grade 2 or higher), moderate to severe atrophic gastritis, dysplasia, or other organ gastrointestinal disease.

2. Patients with a history of abdominal surgery (except for appendectomy and cesarean section).

3. Patients with immune system defects (such as leukaemia or cancer), or those who have been administered immunosuppressive agents or glucocorticoids within the past 3 months.

4. Patients who combined severe cardiac and pulmonary insufficiency, insufficiency of liver (ALT/AST > 1.5 times the upper limit of the normal value) and kidney insufficiency (BUN/Serum Creatinine > the upper limit of the normal value), abnormal of endocrine system( such as diabetes and thyroid dysfunction), abnormal hematopoietic system, and iron deficiency anemia as indicated on hematological examination.

5. Patients with severe anxiety and depression.

6. Patients with psychosis and mental retardation as well as language disorder precluding the ability of filling scales or recording symptoms.

7. Pregnant (a female of childbearing potential with a positive pregnancy test) or lactating females; or patients of childbearing potential without effective contraception.

8. Patients who are known to be allergic to the ingredients of this drug.

9. Patients who are suspected to have or indeed have a history of alcohol or drug abuse.

10. Patients who have participated in a clinical trial in the past 3 months.

11. Patients who are deemed by the investigator as being not suitable for participation in the clinical trial.

Related Conditions & MeSH terms

• Dyspepsia
• Functional Dyspepsia
• Postprandial Distress Syndrome
• Syndrome

Intervention

Drug:
• Zhizhu Kuanzhong Capsule
Zhizhu Kuanzhong Capsule, 3 capsules at a time, 3 times a day, taken orally 10-15 min before meals. an 8-week intervention period
• Zhizhu Kuanzhong Placebo Capsule
Placebo, 3 capsules at a time, 3 times a day, taken orally 10-15 min before meals. an 8-week intervention period

Locations

Country	Name	City	State
Australia	Princess Alexandra Hospital	Brisbane	Queensland
China	Beijing Jishuitan Hospital	Beijing	Beijing
China	Peking Union Medical College Hospital of Chinese Academy of Medical Sciences	Beijing	Beijing
China	Xiyuan Hospital of China Academy of Chinese Medical Sciences	Beijing	Beijing
China	Fujian Provincial Hospital	Fuzhou	Fujian
China	Peking Union Medical College Hospital of Chinese Academy of Medical Sciences	Guangzhou	Guangdong
China	The First Affiliated Hospital of Guangzhou University of Chinese Medicine	Guangzhou	Guangdong
China	Hong Kong Baptist University	Hong Kong	Hongokng
China	Jiangsu Province Hospital	Nanjing	Jiangsu
China	Ruijin Hospital	Shanghai	Shanghai
China	Shengjing Hospital Affiliated to China Medical University	Shenyang	Liaoning
China	Kulun Qimeng Hospital	Tongliao	Neimenggu
China	Wuhan Union Hospital	Wuhan	Hubei
China	Affiliated Hospital of Shaanxi University of traditional Chinese medicine	Xi'an	Shanxi
China	Shaanxi Academy of Traditional Chinese Medicine	Xi'an	Shanxi
China	The Second Affiliated Hospital of Xi'an Jiaotong University	Xi'an	Shanxi

Sponsors (1)

Lead Sponsor	Collaborator
Xiyuan Hospital of China Academy of Chinese Medical Sciences

Countries where clinical trial is conducted

Australia,  China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The proportion of the response at 8 weeks after randomization	Subjects with the functional dyspepsia-postprandial distress syndrome are self-rated on the Visual Analogue Score (VAS) which is a scale of 0-10, with subjects indicating the degree of discomfort on a 10 cm ruler marked 0- "Asymptomatic or No Discomfort "to 10- "Extreme Severe or Extreme Discomfort "at its head and tail, respectively. The record is made once a day and 7 days a week via a diary card. For VAS scores for postprandial fullness discomfort and early satiety, the integral average for both symptoms over the past week is evaluated, and a 50% decrease from baseline in the integral average at 8 Weeks is recorded as a response.	up to 8 weeks
Secondary	The change of VAS score of each symptom of functional dyspepsia	On the diary cards, subjects recorded the Visual Analogue Score (VAS) of each symptom of the functional dyspepsia daily. VAS is scored on a scale of 0-10 which the higher the score, the severer the symptom is. The record is made once a day and 7 days. The investigators use the average of the weekly VAS scores as the symptom intensity score for this week, with one VAS score per week. The change in the score of each symptom at 8 weeks after randomization relative to the baseline is evaluated.	Up to 8 weeks
Secondary	Overall treatment response rate	The overall treatment efficacy is evaluated using a 7-point Likert Overall Evaluation Scale (OTE). The clinical investigators asked the subjects the following questions weekly: "In the last week, how much have your dyspeptic symptoms been alleviated as compared to pre-treatment? " There are 7 options: ? the symptoms improved significantly, ? the symptoms improved, ? the symptoms improved slightly, ? the symptoms did not change, ? the symptoms aggravated slightly, ? the symptoms aggravated, ? the symptoms aggravated significantly. At the last visit time point of the treatment cycle, patients who selected ? and ? were defined as treatment responders, and those who selected ?-? were defined as non-responders. The response rate at 8 weeks after randomization between the groups are compared for differences.	Up to 8 weeks
Secondary	Short Form Nepean Dyspepsia Index (SFNDI)	Short Form-Nepean Dyspepsia Index (SFNDI) is a reliable and valid measure of quality of life in functional dyspepsia with 10 items which questions are about how subjects stomach pain, discomfort, or other epigastric symptoms over the last 14 days affect their lives. Add up the ten items for each of the five sub-scale scores (range of each sub-scale 2-10). The changes of SFNDI score at 4 weeks and 8 weeks after randomization relative to the baseline are calculated.	Up to 8 weeks
Secondary	Hospital Anxiety and Depression Scale score	The Hospital Anxiety and Depression Scale (HAD) is mainly used in patients in general hospitals which provides two sets of tests to assess the state of anxiety and depression, respectively. Among them, A stands for anxiety items, D stands for depression items, and each item is scored at four levels. Each of the two sets of items are superimposed to obtain their respective total score. A total score of 0 to 7 indicates normal, 8 to 10 indicates borderline abnormal, and 11 to 21 indicates abnormal. The changes of HAD score at 4 weeks and 8 weeks after randomization relative to the baseline are calculated.	Up to 8 weeks